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COVID-19 disease results in a wide spectrum of clinical 
manifestations including flu-like symptoms, difficulty in breathing, 
blood and circulatory complications, gastrointestinal symptoms, 
hepatocellular injury, hyperglycaemia and ketosis, neurological 
illnesses, ocular symptoms and dermatological complications.[1] These 
effects are thought to occur as a result of angiotensin-converting 
enzyme 2-mediated cellular viral entry, tissue damage, dysregulation 
of the renin-angiotensin-aldosterone system, systemic release of 
cytokines, and dysfunctions in the microcirculation.[2,3]
Several reports have documented an increased incidence of venous 
thromboembolic events,  including pulmonary embolism (PE), among 
critically ill patients with COVID-19 admitted to hospitals, including 
intensive care units (ICUs).[2,4-11] The mechanism of thromboembolic 
events seems to be stimulated by excessive thrombin production, 
inhibition of fibrinolysis and deposition of antiphospholipids and 
thrombi, as well as microvascular dysfunction in multiple vascular 
beds including the lungs, brain, kidneys and heart.[1] COVID-19 is 
also known to predispose patients to systemic inflammation, which 
has been reported to increase the risk of deep-vein thrombosis, with 
PE seen in 16.7 - 47% of patients admitted to ICUs.[2]
Little is known about the incidence or prevalence of PE in non-
hospitalised patients diagnosed with a milder form of the disease. 
Anecdotal evidence during the early period of the pandemic at 
our facility, the Department of Nuclear Medicine at Universitas 
Academic Hospital in Bloemfontein, South Africa (SA), suggested 
that some non-hospitalised patients diagnosed with mild COVID-19 
were presenting later with persistent or new-onset cardiopulmonary 
symptoms after de-isolation. Ventilation/perfusion (VQ) single-
photon emission computed tomography/computed tomography 
(SPECT/CT) studies performed in those with raised D-dimer levels 
revealed perfusion defects in keeping with PE.
Objectives
To assess the prevalence of PE in this cohort of patients with raised 
D-dimer levels.
Methods
Ethics approval was obtained from the Health Sciences Research 
Ethics Committee at the University of the Free State (ref. no. UFS-
HSD2020/1544/2411).
Study design and location
The study was a retrospective cohort study conducted in a tertiary 
institution.
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Background. Pulmonary embolism (PE) is a known complication of COVID-19 disease. The mechanism of thromboembolic events appears 
to be stimulated by excessive thrombin production, inhibition of fibrinolysis and deposition of antiphospholipids and thrombi, as well as 
microvascular dysfunction in multiple vascular beds. The occurrence of PE has been well demonstrated in hospitalised patients with severe 
disease. Very few data are available on its incidence or prevalence in non-hospitalised patients diagnosed with a milder form of the disease.
Objectives. To assess the prevalence of PE in non-hospitalised patients diagnosed with mild COVID-19 who presented with raised D-dimer 
levels and persistent or new-onset cardiopulmonary symptoms.
Methods. This was a retrospective study conducted in the Department of Nuclear Medicine at Universitas Academic Hospital, Bloemfontein, 
South Africa. We reviewed the studies of 65 non-hospitalised patients with COVID-19 referred to the department from July 2020 to January 
2021 for a perfusion-only single-photon emission computed tomography/computed tomography (SPECT/CT) study or a ventilation/
perfusion (VQ) SPECT/CT study. All 65 patients had raised D-dimer levels with persistent, worsening or new-onset cardiopulmonary 
symptoms after the diagnosis of COVID-19.
Results. Sixty-five patients were studied. The median (interquartile range) age was 46 (41 - 54) years and the majority (88.2%) were female. 
There were 22 patients (33.8%) with lung perfusion defects in keeping with PE. Two of these patients had a false-negative computed 
tomography pulmonary angiography (CTPA) study for PE performed the same day as their VQ SPECT/CT study.
Conclusions. We confirm a high prevalence of PE in non-hospitalised patients diagnosed with mild COVID-19 who presented with raised 
D-dimer levels and persistent or new-onset cardiopulmonary symptoms. We recommend that irrespective of disease severity, hospitalised 
and non-hospitalised patients with COVID-19 presenting with persistent or new-onset cardiopulmonary symptoms and raised D-dimer 
levels should be investigated further for PE.
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Study population
We reviewed all the perfusion-only SPECT/CT and VQ SPECT/CT 
studies of 184 patients who were investigated for PE between July 2020 
and January 2021. Sixty-five patients who met the inclusion criteria 
were included in the study. All had raised D-dimer levels and persistent 
or new-onset cardiopulmonary symptoms after de-isolation. None 
had been hospitalised for severe disease. Forty-seven patients had a 
perfusion-only SPECT/CT study as their initial study, while 18 had a 
VQ SPECT/CT study. Perfusion-only studies were performed because 
earlier on in the pandemic we were being cautious with ventilating 
patients owing to potential spread of infection. It is usually routine 
practice in our facility for patients with PE to have a repeat study 
3  months after initiating therapeutic anticoagulation. However, only 
12 patients came for a follow-up VQ SPECT/CT study 3 months after 
initiation of therapeutic anticoagulation for PE.
Inclusion criteria
• Non-hospitalised de-isolated patients diagnosed with mild 
COVID-19 infection
• Age ≥18 years
• Raised D-dimers
• Persistent or new-onset cardiopulmonary symptoms after de-isolation.
Exclusion criteria
• All patients without a diagnosis of COVID-19
• Patients diagnosed with severe COVID-19
• All hospitalised patients diagnosed with COVID-19.
Equipment
Ventilation studies were performed with 20 - 25 mCi of technetium-99 
metastable diethylenetriamine pentacetate, using the SmartVent 
radioaerosol delivery system (Diagnostic Imaging Ltd, UK). Perfusion 
studies were performed with 3 - 5 mCi of technetium-99 macro-
aggregated albumin.
Images were acquired with either a 16-slice SPECT/CT camera 
(Siemens Symbia T16 TruePoint; Siemens Medical Solutions USA, 
Inc.) or a 2-slice SPECT/CT camera (Siemens Symbia T2 TruePoint; 
Siemens Medical Solutions USA, Inc.). Both cameras are dual-headed 
gamma cameras, with similar work stations and processing units.
Acquisition protocol
Both gamma cameras were equipped with a low-energy high-
resolution collimator. For those patients who had ventilation studies 
done, SPECT imaging was acquired immediately after ventilation of 
the radioaerosol at 15 s/stop, with 3° steps, in a 128 × 128 matrix. 
Then perfusion SPECT imaging was acquired after injection of the 
perfusion tracer at 12 s/stop, with 3° steps, in a 128 × 128 matrix. 
This was followed by a low-dose non-contrast chest computed 
tomography scan, with the patient remaining in the same position.
Image processing
Images were processed using the Syngo work stations for both 
gamma cameras. SPECT images were reconstructed using an iterative 
algorithm, and SPECT/CT fusion images were obtained using the 
multimodality Syngo imaging software on the workstation.
Image interpretation
Two nuclear medicine physicians with combined experience of 
36  years (27 and 9 years) interpreted the images. Interpretation of 
the VQ SPECT/CT studies was based on the accepted European 
guidelines, using at least one large segmental or two subsegmental 
unmatched perfusion defects for the diagnosis of PE.[12] Interpretation 
of the perfusion-only SPECT/CT study was based on a modification 
of the Prospective Investigative Study of Acute Pulmonary Embolism 
Diagnosis study, using at least one large wedge-shaped segmental 
perfusion defect, with normal or near-normal CT findings in that 
segment for the diagnosis of PE.[13,14] These findings were not compared 
with a gold standard, as there is no available modality alone good 
enough to serve as a gold standard for the diagnosis of PE. However, for 
those patients who had follow-up studies, an improvement in the size 
of the perfusion defects and symptomatic improvement 3 months after 
initiating anticoagulation was used as a confirmation for PE.
Data analysis
Data from each patient were collected using Excel 2019 (Microsoft, 
USA) and analysed using the statistical package Stata version 16 
(StataCorp, USA).
Statistical analysis
We reported frequencies and percentages for categorical variables, 
and medians and interquartile ranges (IQRs) for continuous variables. 
Associations of age, time between COVID-19 infection and the 
scan, symptoms prompting the scan, D-dimer levels and COVID 
pneumonia with PE were evaluated using the Wilcoxon rank-sum 
test for comparison of continuous variables and Pearson’s χ2 test for 
categorical variables. We used binary logistic regression to determine 
the effect size of associations of these covariates with PE, reporting 
odds ratios (ORs) and 95% confidence intervals (CIs). A two-tailed 
p-value <0.05 was considered statistically significant.
Results
Sixty-five patients were enrolled during the study period between July 
2020 and January 2021. The median (IQR) age was 46 (41 - 54) years, 
and the majority (89.2%) were female (Table 1). All patients had raised 
D-dimer levels and new-onset or persistence of cardiopulmonary 
symptoms. The most common symptom was shortness of breath 



























































Fig. 1. Distribution of symptoms prompting referral for the study.
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Table 1. Demographic and clinical characteristics of the patients (N=65)
Characteristics
Age (years), median (IQR) 46 (41 - 54)
Sex, n (%)  
Female 58 (89.2)
Male 7 (10.8)
Time between COVID-19 infection and scan (days), median (IQR) 15 (14 - 25)
D-dimers (mg/L), median (IQR) 0.34 (0.28 - 0.81)
Pulmonary embolism, n (%)  
No 43 (66.2)
Yes 22 (33.8)
COVID lungs, n (%)
No 39 (60.0)
Yes 26 (40.0)
Follow-up study, n (%)  
None 42 (75.0)
VQ SPECT/CT scan 14 (25.0)
IQR = interquartile range; VQ SPECT/CT = ventilation/perfusion single-photon emission computed tomography/computed tomography.
Table 2. Associations of SPECT/CT findings with pulmonary embolism
        Pulmonary embolism
OR (95% CI) p-value No (N=43) Yes (N=22)
Age (years), median (IQR) 45 (39 - 54) 48 (43 - 54) 1.04 (0.98 - 1.10) 0.267
Interval between COVID-19 infection and VQ scan (days), 
median (IQR)
15 (14 - 25) 15 (12 - 25) 1.02 (0.98 - 1.05) 0.796
Symptoms prompting VQ scan, n (%)
Shortness of breath 0.249*
No 15 (34.9) 4 (18.2) 1.00 (reference)
Yes 28 (65.1) 18 (81.8) 2.41 (0.69 - 8.43)
Tachycardia 0.868
No 34 (79.1) 17 (77.3) 1.00 (reference)
Yes 9 (20.9) 5 (22.7) 1.38 (0.37 - 5.10)  
Chest pain 0.545
No 24 (55.8) 14 (63.6) 1.00 (reference)
Yes 19 (44.2) 8 (36.4) 0.72 (0.25 - 2.08)  
Cough  0.999
No 41 (95.3) 21 (95.5) 1.00 (reference)
Yes 2 (4.7) 1 (4.5) 0.98 (0.08 - 11.40)  
Haemoptysis 0.545*
No 41 (95.3) 22 (100.0) 1.00 (reference)
Yes 2 (4.7) 0 (0.0) Omitted
Pulmonary hypertension 0.999*
No 42 (97.7) 22 (100.0) 1.00 (reference)
Yes 1 (2.3) 0 (0.0) Omitted
Fatigue 0.111*
No 43 (100.0) 20 (90.9) 1.00 (reference)
Yes 0 (0.0) 2 (9.1) Omitted
D-dimers (mg/L), median (IQR) 0.31 (0.26 - 0.74) 0.41 (0.31 - 0.87) 1.07 (0.54 - 2.09) 0.061
COVID pneumonia, n (%) 0.087
No 29 (67.4) 10 (45.5) 1.00 (reference)
Yes 14 (32.6) 12 (54.5) 2.49 (0.87 - 7.13)
SPECT/CT = single-photon emission computed tomography/computed tomography; IQR = interquartile range; VQ = ventilation/perfusion.
*p<0.05 (Fisher’s exact test).
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All the patients had lung perfusion studies 
performed after de-isolation, 10 - 90 days 
after the diagnosis of COVID-19 infection, 
with 47 (72.3%) of them having a perfusion-
only SPECT/CT study, while only 18 (27.7%) 
had a VQ SPECT/CT study. Of these 65 
patients, 12 (18.5%) had a follow-up VQ 
SPECT/CT study 3 months after their initial 
study. These follow-up studies showed 
either partial or complete resolution of the 
perfusion defects seen earlier.
There were 22 patients (33.8%) with lung 
perfusion defects in keeping with PE. Fourteen 
(63.6%) of the 22 patients with PE had one 
large single segmental perfusion defect, 6 
(27.3%) had two large segmental perfusion 
defects, while only 2 (9.1%) had three large 
segmental perfusion defects.
The median (IQR) age of the patients with 
PE was not significantly different from that 
of the patients without (48 (43 - 54) v. 45 
(39 - 54) years, respectively; p=0.267), and the 
difference between the median (IQR) D-dimer 
levels in patients with and without PE was of 
marginal significance (0.41 (0.31 - 0.87) mg/L 
v. 0.31 (0.26 - 0.74) mg/L; p=0.254). For every 
0.1 unit increase in D-dimer level, patients had 
a 7% increased odds of presenting with PE 
(OR 1.07; 95% CI 0.54 - 2.09; p=0.060). Those 
who had COVID pneumonia were more likely 
to have PE. However, this was of marginal 
significance (OR 2.49; 95% CI 0.87 - 7.13; 
p=0.087) (Table 2).
Discussion
This study shows that of non-hospitalised 
patients with raised D-dimers and persistent 
or new-onset cardiopulmonary symptoms 
diagnosed with mild COVID-19 disease, 
about a third were diagnosed with PE on 
perfusion-only or VQ SPECT/CT studies.
PE is a known thrombotic complication 
that has been associated with COVID-19 
infection.[6] Numerous studies have shown 
the prevalence of PE in hospitalised patients 
with severe disease,[2,4-11] but there are not 
yet sufficient data on patients like ours, with 
persistent cardiopulmonary symptoms after 
recovery from mild disease. However, some 
case reports have reported the occurrence of 
PE in non-hospitalised patients diagnosed 
with COVID-19 infection.[15-18]
In our study, there were 22 patients 
(33.8%) with lung perfusion defects in 
keeping with PE (Figs 2 and 3). We suspect 
that the significant number of cases with 
PE in our cohort was due to the peculiar 
characteristics of our study population 
(raised D-dimer levels and persistent or 
new-onset cardiopulmonary symptoms). 
If we were to include all non-hospitalised 
patients diagnosed with mild COVID-19 
disease, we would probably have a lower 
percentage of patients with PE. Twelve out 
of the 22 patients with PE had follow-up VQ 
SPECT/CT studies 3 months after initiation 
of therapeutic anticoagulation. These follow-
up studies showed some form of defect 
resolution ranging from partial to complete, 
which corresponded with symptomatic 
improvement (Fig. 3).
Many of the studies that have looked at the 
incidence of PE in COVID-19 infection used 
CTPA as the diagnostic modality. However, 
CTPA has limitations in the diagnosis of 
chronic PE and detection of peripheral 
emboli, for which it has low sensitivity. [12,19] 
In our study, we had two cases of false-
negative CTPA studies, with a positive VQ 
SPECT/CT study performed the same day 
(Fig. 4). These patients both presented with 
persistent cardiopulmonary symptoms 3 
months after the diagnosis of COVID-19 
infection and were probably cases of chronic 
PE. It is therefore likely that CTPA may miss 
most of the chronic presentations and cases 
with peripheral emboli.
Hospitalised patients with COVID-19 
infection are likely to receive therapeutic 
or prophylactic anticoagulation and to have 
investigations performed to diagnose PE. 
This is not the case for non-hospitalised 
patients, in whom there is a high chance 
of PE going unnoticed, which could 
predispose them to future complications 
such as pulmonary hypertension and/or 
Fig. 3. Ventilation/perfusion single-photon emission computed tomography/computed tomography 
images showing some resolution of the defect seen in Fig. 2, 3 months after initiating anticoagulation. 
The bottom images are the ventilation images confirming a mismatch of the perfusion defect.
Fig. 2. Perfusion single-photon emission computed tomography/computed tomography images showing a 
perfusion defect (crosshair) in the lateral segment of the right middle lobe prior to anticoagulation therapy.
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right heart failure. In addition, developing 
a second PE could be fatal in this category 
of patients, especially if the first episode was 
not diagnosed and treated.
Reports in the literature have suggested 
that even with prophylactic anticoagulation, 
the incidence of thrombotic complications 
in patients with COVID-19 infection is 
high. [8,10] One of the patients in our cohort 
was actually on anticoagulation prophylaxis 
with a novel oral anticoagulant, starting on 
the day of diagnosis of COVID-19 infection 
and 2 days after symptom onset (fever, 
headache and body pains). She developed 
chest pain shortly before de-isolation. This 
pain was persistent for about 8 weeks before 
she reported for a VQ study, which was 
positive for PE (Figs 5 and 6). 
We believe that going forward, even after 
the end of this pandemic, there may be a rise 
in the incidence of pulmonary hypertension 
and right heart failure from undetected and 
untreated PE in non-hospitalised patients 
with COVID-19 infection. In our facility, 
we are already beginning to see an increase 
in referrals for VQ studies to diagnose PE 
in patients with unexplained pulmonary 
hypertension. It is also likely that some 
of the cardiopulmonary symptoms being 
associated with ‘long’ COVID may in fact be 
due to undetected and untreated PE.
Study limitations
Some limitations have been observed in this 
study, which may contribute to the high 
prevalence of PE. First, there is a possibility 
of increased false-positive rates of PE when 
perfusion-only studies are performed 
without ventilation. Second, we do not have 
an accurate pretest probability for all the 
patients, and we have not been able to 
rule out other risk factors for PE in these 
patients. Third, we are not certain whether 
the referral doctors correctly diagnosed all 
these patients as having mild COVID-19 
infection, and there is a possibility that some 
of them may have had moderate disease. 
We therefore recommend that a proper 
prospective multicentre study be carried 
out in this patient population in SA, as this 
will show the true incidence of PE in non-
hospitalised patients diagnosed with mild 
COVID-19 infection.
Conclusions
PE is not an uncommon occurrence in a 
certain category of non-hospitalised patients 
diagnosed with mild COVID-19 infection 
who present with raised D-dimer levels and 
persistent or new-onset cardiopulmonary 
symptoms. This information is important 
for the scientific community and healthcare 
Fig. 4. Ventilation/perfusion single-photon emission computed tomography/computed tomography 
images confirming an unmatched large perfusion defect in the lateral segment of the right middle 
lobe in a patient with persistent cardiopulmonary symptoms 3 months after the diagnosis of COVID. 
A computed tomography pulmonary angiography study done earlier the same day was negative for 
pulmonary embolism.
Fig. 5. Perfusion single-photon emission computed tomography/computed tomography images showing 
large perfusion defects in the posterior and lateral basal segments of the right lower lobe in a patient on 
prophylactic anticoagulation.
Fig. 6. Ventilation/perfusion single-photon emission computed tomography/computed tomography 
images demonstrating normal ventilation (bottom images) in the same case as in Fig. 5, thus confirming 
pulmonary embolism.
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workers. We recommend that irrespective of the severity of COVID-
19 infection, hospitalised and non-hospitalised patients with raised 
D-dimer levels and persistent or new-onset cardiopulmonary 
symptoms be investigated for PE with a modality that can detect 
both acute and chronic cases.
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